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Abstract
Introduction: Interleukin-6 (IL-6) is an important mediator of inflammation. In addition to cells involved in inflammation,
sensory nociceptive neurons express the IL-6 signal-transducer glycoprotein 130 (gp130). These neurons are not only
involved in pain generation but also produce neurogenic inflammation by release of neuropeptides such as calcitonin
gene-related peptide (CGRP). Whether IL-6 activation of sensory neurons contributes to the induction of inflammation
is unknown. This study explored whether the action of IL-6 on sensory neurons plays a role in the generation of
neurogenic inflammation and arthritis induction.
Methods: In SNS-gp130−/− mice lacking gp130 selectively in sensory neurons and appropriate control littermates
(SNS-gp130flox/flox), we induced antigen-induced arthritis (AIA), and assessed swelling, histopathological arthritis scores,
pain scores, expression of CGRP in sensory neurons, serum concentrations of CGRP and cytokines, and the cytokine
release from single cell suspensions from lymph nodes and spleens. In wild-type mice CGRP release was determined
during development of AIA and, in cultured sensory neurons, upon IL-6 stimulation.
Results: Compared to SNS-gp130flox/flox mice SNS-gp130−/− mice showed significantly weaker initial swelling, reduced
serum concentrations of CGRP, IL-6, and IL-2, no inflammation-evoked upregulation of CGRP in sensory neurons, but
similar histopathological arthritis scores during AIA. During the initial swelling phase of AIA, CGRP was significantly
increased in the serum, knee and spleen. In vitro, IL-6 augmented the release of CGRP from cultured sensory neurons.
Upon antigen-specific restimulation lymphocytes from SNS-gp130−/− mice released more interleukin-17 and interferon-γ
than lymphocytes from SNS-gp130flox/flox mice. In naive lymphocytes from SNS-gp130flox/flox and SNS-gp130−/− mice
CGRP reduced the release of IL-2 (a cytokine which inhibits the release of interleukin-17 and interferon-γ).
Conclusions: IL-6 signaling in sensory neurons plays a role in the expression of arthritis. Selective deletion of gp130
signaling in sensory neurons reduces the swelling of the joint (most likely by reducing neurogenic inflammation) but
increases some proinflammatory systemic cellular responses such as the release of interleukin-17 and interferon-γ from
lymphocytes upon antigen-specific restimulation. Thus IL-6 signaling in sensory neurons is not only involved in pain
generation but also in the coordination of the inflammatory response.
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Introduction
The proinflammatory cytokine interleukin-6 (IL-6) is a
key player in innate immunity and joint inflammation
including human rheumatoid arthritis (RA) [1–4], and
therefore it has been developed into a target of disease-
modifying drugs. Tocilizumab (an IL-6 receptor-specific
antibody) and tofacitinib (a JAK inhibitor) have been ap-
proved for RA therapy, and sirukumab (an IL-6-specific
antibody) and sarilumab (an IL-6 receptor-specific anti-
body) are promising compounds in phase III clinical
development [4].
IL-6 binds to membrane-bound IL-6 receptor (IL-6R)
or to soluble IL-6 receptor (sIL-6R), which is present in
the plasma. Because IL-6/sIL-6R complexes can bind to
cells without membrane-bound IL-6R (a process called
transsignaling [4]), IL-6 can act on many different cell
types such as immune cells, osteoclasts, and others even
if they do not express membrane-bound IL-6R [2, 4].
Essential for the activation is the transmembrane signal-
transducing subunit glycoprotein 130 (gp130) [3, 4], which
is ubiquitously expressed. While inhibition of IL-6 signal-
ing significantly attenuates murine arthritis [5–7], hyper-
active gp130 signaling exacerbates inflammation [8].
IL-6 acts also on nociceptive neurons and is therefore
regarded as a putative pain mediator [9–11]. In fact, dor-
sal root ganglion (DRG) neurons, the cell bodies of
sensory neurons, express the signal transducer gp130
[11, 12], and gp130 expressed in nociceptive sensory
neurons is now considered a key regulator of the in-
duction and maintenance of mechanical hyperalgesia
[13–15]. Upon activation, a proportion of the DRG neu-
rons can also release neuropeptides such as substance P
and calcitonin gene-related peptide (CGRP) into the
tissue and cause a so-called neurogenic inflammation
[16–18]. Remarkably, the levels of these neuropeptides
and IL-6 were shown to be enhanced in serum and syn-
ovial fluid of RA and osteoarthritis patients [19]. An in-
triguing hypothesis is, therefore, that IL-6 causes
enhanced release of neuropeptides from sensory neurons
and that part of the proinflammatory effect of IL-6 is
produced via the nervous system.
In order to specifically address the role of IL-6 stimu-
lation of sensory neurons, we studied the development
of antigen-induced arthritis (AIA) in SNS-gp130−/−
mice, which lack the IL-6 signal-transducing receptor
subunit gp130 selectively in primary sensory neurons. In
SNS-gp130−/− mice the Cre recombinase is under the
transcriptional control of the gene of the sodium chan-
nel Nav1.8, which is selectively expressed in nociceptive
sensory neurons [14], and therefore gp130 is selectively
deleted in nociceptive primary sensory neurons. For
comparison we used their control floxed littermates
(SNS-gp130flox/flox), in which gp130 remains intact. Fur-
thermore, we tested whether CGRP is released during
developing inflammation and whether IL-6 can cause re-
lease of CGRP from sensory neurons. We used the
model of unilateral AIA in mice.
AIA, originally described by Brackertz et al. [20], is a T
cell-mediated joint inflammation whose histopathology
in the affected joint shows many similarities to RA. In
immunized animals, AIA can be induced after injection
of the antigen mBSA into the knee joint as unilateral
monoarthritis. Advantages are the precise starting point
of arthritis, defined by the intraarticular injection of the
antigen into the knee joint, the incidence of 100 %, and
the reproducible time course. It shows a transition from
an acute stage with strong swelling, dense infiltration of
the synovial membrane by granulocytes and exudation
of granulocytes into the joint space to a chronic stage
with hyperplasia of synovial lining cells, infiltration of
the synovial membrane by mononuclear cells, fibrosis of
the synovial membrane and the periarticular tissue, and
some destruction of cartilage. The unilateral process al-
lows using side-by-side comparison. The AIA model is
extensively used for pain research. In animals with AIA
the level of IL-6 in serum and synovial fluid is increased
and shows a strong correlation with the severity of the
disease [21].
We found that SNS-gp130−/− mice show significantly
less swelling of the knee joint than SNS-gp130flox/flox mice,
and no upregulation of CGRP in sensory neurons as in
wild-type and SNS-gp130flox/flox mice indicating that IL-6
effects on sensory neurons contribute to the inflammatory
swelling. CGRP is released within the first hours of devel-
oping AIA and IL-6 causes release of CGRP from cultured
sensory neurons. The serum of SNS-gp130−/− mice at day
3 of AIA exhibited lower concentrations of CGRP, IL-6,
and IL-2 than the serum of SNS-gp130flox/flox mice. The
antigen-specific-restimulated lymphocytes isolated from
lymph nodes and the spleen of SNS-gp130flox/flox mice
released significantly more interleukin-17 (IL-17) and
interferon-γ (IFNγ) than lympocytes from SNS-gp130flox/flox
mice. Thus the loss of neuronal IL-6 signaling also affects
the cellular immune response.
Methods
Animals
We used 51 C57BL/6 J male/female wild-type (WT)
mice (12–14 weeks, 17–22 g, supplied by the Animal
Facility of the University Hospital Jena), 26 male/female
SNS-gp130−/− mice and 28 male/female control litter-
mates (SNS-gp130flox/flox) (8–16 weeks, 20–31 g, bred
and genotyped by the Innsbruck Medical University).
SNS-gp130−/− mice were generated using the Cre re-
combinase floxP strategy. Homozygous mice carrying
the loxP-flanked (floxed) gp130 allele [22] were mated
with mice which express Cre recombinase selectively
in sensory neurons using promoter elements of the
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Nav1.8 gene (Scn10a) [23]. The generation of mice at
the University of Innsbruck was approved by the
Austrian Bundesministerium fuer Wissenschaft und
Forschung. All experiments on animals at the University
of Jena were approved by the Thüringer Landesamt für
Lebensmittelsicherheit and Verbraucherschutz, Abteilung
Gesundheitlicher Verbraucherschutz, Veterinärwesen,
Pharmazie (registration number No. 02-033/10). At
the end of the experiments mice were killed by cer-
vical dislocation under isoflurane anesthesia.
Arthritis induction and assessment
Mice were immunized at 21 and 14 days before AIA in-
duction with subcutaneous injection of 100 μg of meth-
ylated bovine serum albumin (mBSA), the antigen
(Sigma-Aldrich, Taufkirchen, Germany), emulgated with
50 μl of complete Freund’s adjuvant (CFA; Sigma-
Aldrich), supplemented to 2 mg/ml Mycobacterium
tuberculosis, strain H37Ra (Difco, Detroit, MI, USA).
Additionally, 5 × 108 heat-inactivated Bordetella pertussis
germs (Chiron-Behring, Marburg, Germany) were ap-
plied intraperitoneally. For induction of monoarticular
AIA 100 μg mBSA in 25 μl 0.9 % NaCl was injected
into the right knee joint cavity on day 0. Im-
munization control animals (IC) received 25 μl 0.9 %
NaCl intraarticularly. A flare-up reaction was induced
by another intraarticular injection of 100 μg mBSA
21 days after primary arthritis induction. The knee
injections were performed under short isoflurane
(2.5 %) anesthesia.
Knee swelling was assessed by M. Ebbinghaus by
measuring the mediolateral joint diameter using an
Oditest vernier caliper (Kroeplin, Schlüchtern, Germany).
For histopathology, knee joints were removed, fixed in
4.5 % formalin, decalcified in EDTA, embedded in par-
affin and cut into 3 μm frontal sections, which were
stained with hematoxylin and eosin (H&E). The path-
ologist who scored the arthritis (M. Gaida) was un-
aware of the experimental groups, and arthritis was
assessed as previously established [24]. Signs of acute
inflammation (infiltration of the synovial membrane by
granulocytes and exudation of granulocytes into the
joint space), and chronic inflammation (hyperplasia of
synovial lining cells, infiltration of the synovial mem-
brane by mononuclear cells, fibrosis of the synovial
membrane and the periarticular tissue) were scored:
0: no, 1: mild, 2: moderate, 3: severe changes (+1 if
fibrin exudation in the joint space). Cartilage surface
defects with cell necrosis were scored: 0: no damage,
1: <5 %, 2: 5–10 %, 3: 11–50 %, and 4: >50 % of the
cartilage surface affected. Damage to bone was eva-
luated: 0: no, 1: mild, 2: medium, 3: severe (extensive
area of deep invasive destruction of bone). Scoring
was graded in 0.5 steps.
Pain-related behavior
Secondary mechanical and thermal hyperalgesia at the
hindpaws were assessed as an indicator of pain. After
accommodation to the device the mechanical pain
threshold was assessed with a dynamic plantar esthesi-
ometer (Ugo Basile, Comerio, Italy), which applied in-
creasing pressure at 1 g/s to the paw (cutoff at 10 g).
The latency of the elicited leg withdrawal, which reflects
the mechanical threshold, was averaged from up to three
consecutive stimuli. Two testings before AIA induction
defined the baseline (BL). Thermal hypersensitivity was
assessed using the Hargreaves plantar test (Ugo Basile)
[25]. Three consecutive standardized heat stimuli were
applied to the paw to evaluate the mean withdrawal
latency (cutoff at 20 s). To quantify the magnitude of
hyperalgesia we calculated the area under the curve
(AUC) for the values of the right (ipsilateral side of in-
flammation) and left (contralateral side) paw [26].
Cytokine analysis
Using standard sandwich enzyme-linked immunosorbent
assay (ELISA) procedures [27], cytokines were analyzed
in serum and single cell suspensions from inguinal, pop-
liteal, subaortic lymph nodes and spleens, removed at
day 3 of AIA, and in cell suspensions from spleens from
naïve mice. Primary and biotin-labeled secondary anti-
bodies for IFNγ, IL-2, IL-4, IL-5 and IL-6 were pur-
chased from BD Biosciences (Heidelberg, Germany),
antibodies for IL-17 from R&D Systems (Wiesbaden,
Germany). For quantification, recombinant cytokines
were used as standard.
Because lymphocytes show little basal release of cyto-
kines in vitro, lymphocytes (106 cells/ml) were cultured
for 42 h with either 1 μg/ml plate-bound anti-CD3 anti-
bodies (from 145-2C11 hybridoma cell supernatant) for
overall T cell receptor stimulation, or with 25 μg/ml
mBSA for antigen-specific restimulation. Lymphocytes
from each mouse were stimulated separately and the cy-
tokines were measured, cytokine by cytokine, in aliquots
of the supernatant from the lymphocytes of each mouse.
Each experimental group contained data from the lym-
phocytes of at least six mice.
Serum antibody levels
Total immunoglobulin G (IgG) and IgG specific for
mBSA were determined in serum, obtained at day 3 of
AIA, by ELISA (see [27]). IgG levels are illustrated as
the value of absorbance representing readings obtained
at 492 nm for total IgG and at 405 nm for the IgG
subclasses, respectively.
CGRP analysis and protein assay
CGRP was quantified in serum, tissue extracts from knee
joints, spleens and in supernatants of DRG neuron
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cultures. The tissues were snap-frozen without further
dissection, i.e., the whole organ was used without separ-
ating different tissues. Extracts from snap-frozen tissue
were prepared in an extraction buffer (pH 3.4) contain-
ing protease inhibitors using an ultrasonicator (Covaris,
Brighton, UK) for lysis after manual tissue homo-
genization with liquid nitrogen. Total protein concentra-
tion in extracts was determined with a BCA protein
assay (Thermo Fisher Scientific, Rockford, IL, USA)
according to the manufacturer’s instructions. For CGRP
measurement we used an enzyme immunoassay kit
(Cusabio, Wuhan, China) according to the manufac-
turer’s instructions. The intra-assay coefficient of vari-
ation (CV) was <8 %, the inter-assay CV was <10 % and
the sensitivity limit was 3.9 pg/ml.
Immunohistochemical labeling of CGRP in DRG sections
DRGs from segments L1–5 from both sides were excised
separately, fixed at 4 °C in 4 % paraformaldehyde for
24 h, embedded in paraffin, cut into 5 μm sections,
which were dewaxed and autoclaved for 15 min (120 °C,
1 bar). For CGRP labeling we applied overnight at 4 °C a
mouse reactive anti-CGRP antibody (1:100; polyclonal
against a synthetic rat Tyr-CGRP (23–37) conjugated to
gamma globulin developed in goat; Cat. No BP022, Acris
Antibodies, Herford, Germany). Sections were incubated
for 2 h in biotinylated rabbit anti-goat antibody (1:200;
DAKO, Glostrup, Denmark), then the avidin-biotin
peroxidase complex (Vectastatin Elite ABC Kit, Vector
Laboratories, Burlingame, CA, USA) was applied for
40 min. Sections were developed with Jenchrom px blue
(JenLab, Jena, Germany). In control experiments the
primary antibody was omitted or preincubated with
100 μg/ml CGRP (1–37) for 20 min (Bachem, Bubendorf,
Germany).
The immunohistochemical labeling was evaluated as
previously described [28]. In each second section the
proportion of neuronal profiles with CGRP-like immu-
noreactivity (IR) was determined using a light micro-
scope (Axioplan 2, Zeiss, Jena, Germany) coupled to an
image analyzing system (AxioVision, Zeiss). For each
mouse the average proportion of labeled neuronal pro-
files was calculated. At least 100 neuronal profiles with a
visible nucleus per mouse were counted.
CGRP release from cultured DRG neurons
DRGs from WT mice were dissected, incubated in
125 U/ml collagenase type II (Paesel and Lorei, Hanau,
Germany), diluted in Ham’s F12 (PAA Laboratories,
Piscataway, NJ, USA), for 1 h at 37 °C. After washing,
ganglia were placed in 10,000 U/ml Trypsin (Sigma-
Aldrich), diluted in Dulbecco’s modified Eagle’s medium
(DMEM, Gibco/BRL, Eggenstein-Leopoldshafen, Germany)
for 11 min at 37 °C. Neurons were separated by gentle
agitation and mechanical treatment with a fire-polished
Pasteur pipette. The cell suspension was centrifuged at
500 × g (8 min), finally neurons were resuspended in media
consisting of Ham’s F12, 50 μmol/l β-mercaptoethanol
(Roth, Karlsruhe, Germany), 10 ng/ml nerve growth factor
(Enzo Life Sciences, Lörrach, Germany), 2 mmol/l glu-
tamine (Sigma-Aldrich), 15 % heat inactivated horse serum
(PAA Laboratories), 100 U/ml penicillin, 100 μg/ml
streptomycin (Gibco/BRL). The cell suspension was plated
on poly-L-lysine- (200 μg/ml; Sigma-Aldrich) coated glass
coverslips and kept in a humidified incubator gassed with
5 % CO2 and air at 37 °C. Cells were fed with 1 ml medium
every day.
CGRP release was measured from DRG neurons cul-
tured for 2 days. Basal CGRP production was measured
in the presence of culture medium for 20 min. For
stimulation we applied either 50 mmol/l KCl alone for
20 min, or KCl with IL-6 or/and soluble IL-6 receptor
(sIL6R) (for concentrations see Fig. 6d). Phosphate-
buffered saline (PBS), containing 10 % fetal calf serum,
was added to culture supernatant aliquots to protect
CGRP from degradation. Probes were stored at −20 °C
until usage.
Statistical analysis
Differences were calculated using the two-tailed Stu-
dents t test for unpaired values and the nonparametric
Mann-Whitney U and Kruskal-Wallis test for CGRP
analysis respectively. Arthritis scores and proportions of
labeled neurons were compared using analysis of vari-
ance (ANOVA) followed by pairwise multiple com-
parison procedures (Bonferroni, t test). The correlation
between the histopathological arthritis score and the
joint swelling was analyzed using Spearman’s rank cor-
relation coefficient. Differences in cytokine expression
against baseline were analyzed using the Wilcoxon’s
matched-pairs signed-rank test. Statistical significance
was calculated with SPSS software (v.16.0, Chicago, IL,
USA) and accepted at p < 0.05.
Results
Swelling and pain-related behavior in AIA in
SNS-gp130−/− and SNS-gp130flox/flox mice
Initially we tested whether the deletion of gp130 in sen-
sory neurons impairs the development of AIA. As shown
in Fig. 1a, joint swelling was significantly attenuated in
SNS-gp130−/− mice compared to swelling in SNS-
gp130flox/flox mice. This strong effect of the deletion of
neuronal gp130 was also observed in the flare-up reac-
tion (a second acute reaction), which was evoked by a
further injection of mBSA into the knee joint at 21 days
after the primary AIA induction (Fig. 1b). Differences
between both groups of mice disappeared during the
transition into the chronic phase of AIA from day 7 on.
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We also measured the pain-related behavior (secondary
hyperalgesia at the paws) of SNS-gp130−/− and SNS-
gp130flox/flox mice before and during development of AIA.
In immunized but nonarthritic mice the time to with-
drawal of the leg (indicating withdrawal thresholds) to
mechanical stimuli onto the right hind paw were not dif-
ferent in SNS-gp130−/− (5.9 ± 0.4 s) and SNS-gp130flox/flox
mice (5.8 ± 0.3 s). After AIA induction SNS-gp130flox/flox
mice showed a reduction of mechanical threshold for
withdrawal at the ipsilateral (right) paw and a slight
increase of threshold at the contralateral paw (Fig. 1c,
significant difference between both paws, ANOVA:
F[1, 11] = 28.298; p < 0.001). SNS-gp130−/− mice did
not show such a difference (ANOVA: F[1, 13] = 0.713;
p = 0.414) indicating less mechanical hyperalgesia than
in SNS-gp130flox/flox mice (Fig. 1d). Figure 1e compares
the areas between the curves displayed in Fig. 1c and d.
Testing for thermal hyperalgesia did not show differences
between SNS-gp130flox/flox and SNS-gp130−/− mice (data
not shown).
Histopathological scores of AIA in SNS-gp130−/− and
SNS-gp130flox/flox mice
Although SNS-gp130−/− mice exhibited significantly less
swelling, the histopathological arthritis scores of inflam-
mation and destruction did not show significant differ-
ences between SNS-gp130flox/flox and SNS-gp130−/−
mice, neither on day 3 of acute AIA (Fig. 2a) nor on day
12 after flare-up (Fig. 2b). However, we noted a striking
difference between SNS-gp130−/− and SNS-gp130flox/flox
mice in the relationship between swelling and the histo-
logic arthritis score. Figure 2c displays the value of
swelling of day 1 of flare-up against the corresponding
arthritis score of each mouse. SNS-gp130flox/flox mice
showed a strong correlation of swelling and arthritis
score (r = 0.831, p = 0.002), whereas SNS-gp130−/− mice
Fig. 1 Joint swelling and pain-related behaviors in SNS-gp130flox/flox and SNS-gp130−/− mice after induction of AIA. a. In acute primary AIA
SNS-gp130−/− mice (n = 16) show significantly less joint swelling than SNS-gp130flox/flox mice (n = 19) (F[1, 33] = 9.476; p = 0.004). b. The same
effect was observed in the flare-up reaction (induced 21 days after the primary AIA) up to day 7 (F[1, 19] = 8.438; p = 0.009; n = 10–11 per group).
c. Reduction of mechanical withdrawal threshold at the paw ipsilateral to the inflamed knee and increase in threshold at the paw contralateral to
the inflamed knee in SNS-gp130flox/flox mice (F[1, 11] = 28.298; p < 0.001). d. No significant differences between the ipsilateral and contralateral
paw in SNS-gp130−/− mice after AIA induction (F[1, 13] = 0.713; p = 0.414). In c and d: n = 6–8 per group. e. Areas between the ipsilateral and
contralateral curves in c and d. Values are mean ± SEM, *p < 0.05, **p < 0.01. AIA antigen-induced arthritis, AUC area under the curve, BL baseline
Ebbinghaus et al. Arthritis Research & Therapy  (2015) 17:334 Page 5 of 13
did not (r = 0.267, p = 0.457) indicating that the pro-
cesses of swelling and cellular inflammatory effects in
SNS-gp130−/− mice were not coherent. Figure 2d dis-
plays representative H&E-stained knee joint sections.
Alteration of mediators in the serum and of cellular and
humoral immune responses
Because we were particularly interested in the role of
sensory neurons on the effect of IL-6 signaling in AIA,
we measured the concentration of CGRP and IL-6 in the
serum of SNS-gp130−/− and SNS-gp130flox/flox mice at
day 3 of AIA (Fig. 3). Furthermore we assessed a num-
ber of immune parameters in SNS-gp130−/− and SNS-
gp130flox/flox mice (Figs. 3, 4 and 5).
The serum of SNS-gp130−/− mice contained less
CGRP, IL-6, and IL-2 than the serum of SNS-
gp130flox/flox mice. The concentration of IFNγ was simi-
lar, the concentration of IL-17 in the serum was below the
detection level (Fig. 3).
Furthermore, we measured the in vitro concentra-
tions of a representative variety of TH1-, TH2-, and
TH17-derived cytokines produced in lymph node and
spleen cells. For this purpose we used single cell suspen-
sions from inguinal, popliteal, subaortic lymph nodes and
spleens, removed at day 3 of AIA, and stimulated them
with either anti-CD3 antibodies for overall T cell receptor
stimulation, or with mBSA for antigen-specific resti-
mulation. No significant differences in the release of
cytokines were observed between SNS-gp130flox/flox and
SNS-gp130−/− mice upon unspecific stimulation of cells
with anti-CD3 antibodies (Fig. 4a, b). Only the amount of
IL-2 produced by spleen cells was decreased in SNS-
gp130−/− mice. However, upon antigen-specific resti-
mulation with mBSA, the cells from SNS-gp130−/− mice
released significantly more IL-17 and IFNγ than cells from
SNS-gp130flox/flox mice (Fig. 4c, d).
No differences in the level of immunoglobulins in
serum were detected between both groups of mice, nei-
ther for total immunoglobulins nor immunoglobulins
specific for the antigen mBSA (Fig. 5a, b).
CGRP and inflammation
The lower concentration of CGRP in the serum of SNS-
gp130−/− mice led us to investigate the role of CGRP in
AIA. First, we quantified the proportions of CGRP-
positive lumbar DRG neurons before and during the
acute phase (day 3) and the chronic phase (day 21) of
AIA. In WT mice we found a bilateral increase of the
proportion of DRG neurons expressing CGRP at day 3
of AIA in comparison to the immunized control mice
Fig. 2 Histopathological scores of AIA in SNS-gp130−/− and SNS-gp130flox/flox mice. a. Scores of synovitis and damage to articular cartilage or
bone in both groups of mice at day 3 of primary AIA. b. Scores of inflammation and destruction in both groups of mice at day 12 of flare-up.
Values in a and b are mean ± SEM. c. Correlation between joint swelling and histopathological arthritis score in SNS-gp130flox/flox mice (solid line,
r = 0.831, p = 0.002) and SNS-gp130−/− mice (broken line, r = 0.267, p = 0.457), n = 10–11 per group. d. Representative pictures (100×) of H&E-stained
knee joint sections from SNS-gp130flox/flox and SNS-gp130−/− mice at day 3 of AIA. AIA antigen-induced arthritis, F femur, M meniscus, SL synovial layer,
T tibia,
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(Fig. 6a). Such an increase was not present any more at
day 21 of AIA. At day 3 the SNS-gp130flox/flox mice
showed a similar bilateral upregulation of the CGRP-
positive neurons as WT mice but in SNS-gp130−/− mice
this effect was not observed (Fig. 6b). CGRP-like immu-
noreactivity (CGRP-like IR) was expressed in small- and
medium-sized DRG neurons (Fig. 6c). These data sug-
gest a role of CGRP in the development of AIA, and
they indicate that SNS-gp130−/− and SNS-gp130flox/flox
mice differed in this aspect.
Second, the injection of the antigen mBSA into the
knee joint of immunized mice (induction of AIA) caused
significant swelling of the knee joint within 3 h (Fig. 7a,
AIA) whereas the intraarticular injection of NaCl in im-
munized mice did not cause swelling of the knee (Fig. 7a,
IC). Within 6 h of AIA the CGRP concentration in the
serum, in the knee tissue and in the spleen increased sig-
nificantly (Fig. 7b-d).
Third, in order to test whether there is a link between
IL-6 signaling and the release of CGRP, we tested
whether IL-6 or IL-6/sIL6R complexes caused release of
CGRP from sensory neurons (Fig. 6d). Supernatants
from DRG neurons showed a basal release of CGRP
(14.4 ± 10.1 pg/ml). Depolarization with KCl significantly
increased the CGRP release (Fig. 6d, column 1), IL-6/
sIL6R without KCl had no effect (column 2). However,
either IL-6 alone or IL-6/sIL6R enhanced the release of
CGRP by KCl (columns 3–8). Thus IL-6 signaling
enhances the release of CGRP evoked by depolarization
of the neurons.
Cytokine expression profiles of lymphocytes from naive
SNS-gp130−/− and SNS-gp130flox/flox mice
In order to test whether lymphocytes from SNS-gp130−/−
and SNS-gp130flox/flox mice show per se different reactions
to activation, we stimulated lymphocytes with anti-CD3
and tested how either CGRP, IL-6/sIL-6R, or IL-6/sIL-6R
plus CGRP influence the release of IL-2, IL-17, and IFNγ
(Fig. 8). Both lymphocytes from SNS-gp130−/− and SNS-
gp130flox/flox mice exhibited release of IL-2, IL-17, and
IFNγ upon anti-CD3 stimulation, but the concentration of
the cytokines in the supernatants was similar between ge-
notypes (Fig. 8a, b, c, columns on the left). As expected,
the secretion of IL-2 was significantly reduced by 100 nM
CGRP (see [29]), significantly enhanced by IL-6/sIL-6R,
and significantly reduced by IL-6/sIL-6R plus CGRP
(Fig. 8a, columns on the right). By contrast, the release of
IL-17 was slightly enhanced by 10 pM CGRP and strongly
enhanced by IL-6/sIL-6R alone or by IL-6/sIL-6R in the
presence of CGRP (Fig. 8b). The release of IFNγ was
weakly inhibited by 100 nM CGRP in lymphocytes from
SNS-gp130−/− mice, but strongly enhanced by IL-6/sIL-
6R, an effect, attenuated by CGRP (Fig. 8c). Together,
these data show that both CGRP and IL-6 modified cyto-
kine release with the strongest and opposite modulation
of IL-2 secretion by CGRP and IL-6/sIL-6R. Furthermore,
lymphocytes from SNS-gp130−/− and SNS-gp130flox/flox
mice did not significantly differ concerning their reaction
to anti-CD3, CGRP, and IL-6/sIL-6R stimulation.
Discussion
The study revealed a significant reduction of swelling
during the development of AIA in SNS-gp130−/− mice
in which gp130 signaling was specifically depleted in
sensory neurons. Pain-related behavior was also reduced
in SNS-gp130−/− mice. The serum of SNS-gp130−/− mice
exhibited significantly lower concentrations of CGRP, IL-6,
and IL-2 at day 3 of AIA than the serum of SNS-
gp130flox/flox mice. In wild-type and SNS-gp130flox/flox
mice but not in SNS-gp130−/− mice the proportion of
dorsal root ganglion neurons expressing CGRP was upreg-
ulated during the acute phase of AIA. CGRP was found to
be significantly increased in the knee joint, serum and
spleen during the first hours of AIA indicating the activa-
tion of CGRP-positive sensory neurons. In cultured DRG
neurons CGRP release was evoked by IL-6 signaling. In
Fig. 3 Serum concentrations of CGRP, IL-6, IL-2 and IFNγ in
SNS-gp130flox/flox (black bars, n= 10) and SNS-gp130−/− mice (white bars,
n= 7) on day 3 of AIA. IL-17 was not detectable. Values are mean ± SEM,
*p < 0.05, **p < 0.01. CGRP calcitonin gene-related peptide,
IFNγ interferon-γ, IL interleukin
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naive lymphocytes from both SNS-gp130flox/flox and SNS-
gp130−/− mice CGRP similarly reduced the secretion of
IL-2, which may be responsible for the enhanced release
of IL-17 and IFNγ upon antigen-specific restimulation.
Compared to the lymphocytes of SNS-gp130flox/flox mice,
the lymphocytes from SNS-gp130−/− mice showed an in-
creased release of IL-17 and IFNγ upon antigen-specific
restimulation. Taken together, the data show that gp130
signaling in sensory neurons is an important component
in the development of immune-mediated arthritis.
In SNS-gp130−/− mice the IL-6 signal transducer
gp130 is only deleted in sensory neurons (mice that are
systemically deficient for gp130 are embryonically lethal
[30]). The reduction of swelling in SNS-gp130−/− mice
clearly indicates that sensory neurons are involved in the
early development of inflammation and that IL-6 exerts
part of its proinflammatory role by activating sensory
neurons. The data further support that gp130 signaling
contributes to inflammation-evoked mechanical hyper-
algesia, corresponding to the sensitization of nociceptive
sensory neurons for mechanical stimuli by IL-6 that has
been previously reported for the complete Freund’s adju-
vant and neuropathic pain models [13–15, 31]. During
development of AIA SNS-gp130flox/flox mice showed a
decrease of the withdrawal threshold on the inflamed
side and an increase of the threshold on the nonin-
flamed side. The decrease of the threshold at the side of
inflammation displays the secondary hyperalgesia at the
paw. The increase of threshold at the noninflamed side
(consistently observed in several studies on AIA in mice)
is more difficult to explain. In order to withdraw the
paw from a stimulus the mouse moves the knee joint. If
the mouse withdraws the healthy leg, the inflamed leg is
loaded and may cause discomfort. From rats with AIA
in the knee joint in which static weight bearing can be
measured we know that they put much less weight on
the inflamed side than on the healthy side, i.e., they
avoid to put load on the inflamed side. We believe,
therefore, that the mouse tolerates a higher withdrawal
threshold on the healthy side in order to prevent loading
of the inflamed side. Therefore we propose the left-right
difference as a measure of hyperalgesia. The left-right
difference was significantly lower in SNS-gp130−/− mice
indicating less hyperalgesia in SNS-gp130−/− mice than
in SNS-gp130flox/flox mice.
The main focus of the present study was on the role of
sensory neurons and the IL-6 signaling of sensory neu-
rons in the development of inflammation. Strikingly,
swelling of the joint was reduced in the mice in which
gp130 signaling was selectively deleted in sensory
Fig. 4 In vitro cytokine expression profiles of lymphocytes isolated on day 3 of AIA from SNS-gp130flox/flox and SNS-gp130−/− mice in vitro. a. Cytokine
levels in supernatants of anti-CD3-stimulated spleen cells (IL-2, p = 0.039). b. Cytokine levels in supernatants of anti-CD3-stimulated lymph node cells.
c. Cytokine levels in supernatants of antigen (mBSA)-specific restimulated spleen cells (IL-17, p = 0.035; IFNγ, p = 0.034). d. Cytokine levels in supernatants
of antigen (mBSA)-specific restimulated lymph node cells (IFNγ, p = 0.038). Specifications in brackets define the dilution of the cytokine values. Values
are mean ± SEM, n = 8–10 per group. IFNγ interferon-γ, IL interleukin, mBSA methylated bovine serum albumin
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neurons, which display signatures of reduced excitability
[32]. These data strongly suggest that sensory neurons
contribute to the development of AIA by the mechanism
of neurogenic inflammation. The latter process is largely,
but not exclusively, linked to CGRP that is present in
30–40 % of small- and medium-sized DRG neurons sup-
plying multiple tissues [33]. These peptidergic neurons
rapidly release CGRP upon noxious stimulation [34] and
during development of acute joint inflammation [1, 35].
CGRP is a potent vasodilator and associated with neuro-
genic inflammation [18]. Numerous sensory fibers
containing CGRP are found in close proximity to the
synovial capillary network [36] which produces the syn-
ovial fluid [37]. Here we found a strong CGRP release
into the joint tissue and adjacent tissues in the first
hours of AIA. In order to avoid further release of CGRP
by dissecting procedures we used snap-frozen tissue
blocks, which contained the knee joint and adjacent
structures for the analysis of CGRP release. Therefore
we cannot precisely differentiate how much the individ-
ual tissue types contributed to the CGRP release.
Similar to other models of inflammation [38, 39], we
found a rapid upregulation of CGRP-like IR in lumbar
DRG neurons during AIA, which is evident from the in-
crease of the proportion of neurons expressing CGRP.
Thus CGRP-expressing sensory neurons are markedly
activated at the onset of AIA. Notably, the increase of
the proportion of DRG neurons with upregulation of
CGRP-like IR was observed bilaterally. Bilateral changes
upon unilateral arthritis are common in the AIA model
although the mechanism for such a bilateral effect has
not been discovered [40].
Because CGRP is rapidly increased in the joint during
AIA development, we believe that the activation of neu-
rons by IL-6 and the CGRP release are linked. Several
findings support this view. First, in isolated DRG neu-
rons IL-6 signaling enhances the KCl (depolarization)-
induced release of CGRP. The need of a costimulatory
signal (here KCl) was also observed in other studies on
IL-6-triggered CGRP release [41, 42] suggesting that IL-6
signaling alone is not sufficient to elicit action potentials.
Second, the proportion of DRG neurons expressing
CGRP-like IR was not upregulated in SNS-gp130−/− mice
whereas it was upregulated in SNS-gp130flox/flox and WT
mice. Other data established a direct link between IL-6
signaling and CGRP release. In sensory neurons, gp130
regulates the expression of the transient receptor potential
ankyrin 1 (TRPA1) ion channel, which is relevant for
mechanonociception, and in SNS-gp130−/− mice TRPA1
is significantly less expressed [31]. Importantly, TRPA1 is
also involved in the release of CGRP from sensory neu-
rons [43]. The release of CGRP was also implicated in the
generation of pain in arthritis models [44, 45] showing an-
other link between IL-6 and CGRP.
In support for a role of CGRP and neuronal IL-6 sig-
naling in the development of inflammation we found a
reduction of the concentration of CGRP in the serum of
SNS-gp130−/− mice. Interestingly, the concentrations of
IL-6 and IL-2 were also decreased. It is unclear why the
concentration of these cytokines was reduced in SNS-
gp130−/− mice but the levels of CGRP, substance P and
IL-6 are elevated in serum and synovial fluid of RA and
osteoarthritis patients [19]. Thus the activation of sen-
sory neurons by IL-6 may also regulate the concentra-
tion of IL-6. For example, monocytes, the major source
of IL-6 in serum, and fibroblasts are activated by CGRP
[46, 47]. IL-6 can also be produced in a proportion of
sensory neurons themselves [48–50]. This was not fur-
ther explored.
Interestingly, histopathology did not identify a significant
difference of AIA in SNS-gp130−/− and SNS-gp130flox/flox
mice, neither at the acute nor at the chronic stage.
Fig. 5 Serum immunoglobulin G (IgG) levels on day 3 of AIA. The
amount of total serum IgG (a) as well as IgG specific for the antigen
mBSA (b) do not show significant differences between both groups
of mice. Values are mean ± SEM (n= 8–10 per group). mBSA methylated
bovine serum albumin
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However, histopathology mainly assesses the cellular joint
infiltration that is driven by cytokines, and not the edema
[51]. Notably, in SNS-gp130flox/flox mice the swelling and
the cellular infiltration was highly correlated but such a
correlation was lost in the SNS-gp130−/− mice, i.e., they
had a strong cellular reaction in spite of reduced swelling.
This led to the question whether SNS-gp130−/− and SNS-
gp130flox/flox mice show differences in the immune re-
sponsiveness. The amounts of immunoglobulin in the
serum were not different, but the spleen and lymph node
cell cultures from SNS-gp130−/− mice released more
IL-17 and IFNγ after antigen-specific restimulation. In
particular IL-17 is thought to be a pivotal driving force of
autoimmune inflammation in animal models of arthritis
as well as in human rheumatoid arthritis [52, 53].
A possible explanation for this observation could be
that T cells express receptors for CGRP [54, 55], that
CGRP-positive nerve fibers immunoreactive for CGRP
were detected in spleen and lymph nodes of mice
[54, 56], and that CGRP inhibits antigen-specific T cell
proliferation [55] and accumulation of IFNγ mRNA [29].
Thus the loss of IL-6 signaling in sensory neurons and the
lack of IL-6-induced CGRP secretion may lead to an en-
hanced release of IL-17 and IFNγ in lymphocytes of SNS-
gp130−/− mice. However, neither in naive lymphocytes
from SNS-gp130−/− mice nor from SNS-gp130flox/flox mice
CGRP reduced the release of IL-17 or IFNγ upon anti-
CD3 stimulation. By contrast, as described previously [29],
CGRP at an effective dose reduced the release of IL-2.
This cytokine constrains the T helper 17 cell generation
by STAT5 and reduces the synthesis of IL-17 and IFNγ
in lymphocytes [57–59] thus opposing the stimulating
effect of IL-6 on lymphocytes (see Fig. 8). The reduc-
tion of serum concentration of IL-2 in SNS-gp130−/−
mice may attenuate the inhibitory effect of IL-2, and
this may allow a stronger release of IL-17 and IFNγ in
Fig. 6 Upregulation of the expression of CGRP-like IR in vivo in DRG neurons and CGRP release in vitro from DRG neurons. a. Proportions of CGRP-positive
DRG neurons in the contralateral (c) and ipsilateral (i, side of inflammation) lumbar DRGs in naïve control wild-type (WT) mice (n = 5), immunized WT
mice (n = 4), WT mice at 3 days of AIA (acute, n = 4) and WT mice at 21 days of AIA (chronic, n = 4). b. Proportions of CGRP-positive DRG neurons in
the contralateral and ipsilateral lumbar DRGs in SNS-gp130flox/flox (n = 4–6) and SNS-gp130−/− mice (n = 5) at 3 days of AIA (acute) and at day 12 of
flare-up (chronic). Significant differences occur between SNS-gp130flox/flox and SNS-gp130−/− mice in the “acute phase”. Values are mean ± SEM. c. DRG
section showing CGRP-positive neurons (see arrow) after incubation with anti-CGRP antibody (left). Control staining of DRG section without anti-CGRP
antibody (middle) and with CGRP (1–37)-preincubation of the anti-CGRP antibody (right). Scale bar = 10 μm. d. CGRP release in vitro from DRG neurons
from WT mice. Illustrated CGRP concentrations in the supernatants show the evoked release minus the basal production in the same time. *p < 0.05,
**p < 0.01 significant differences referring to “only KCl”. #p < 0.05, ##p < 0.01 significant differences between different concentrations of IL-6/sIL6R. Values
are mean ± SD; n = 5 each. CGRP calcitonin gene-related peptide, CGRP-like IR CGRP-like immunoreactivity, DRG dorsal root ganglion, IL-6 addition of
IL-6 to the culture medium, sIL6R addition of sIL6R to the culture medium, KCl depolarization of neurons by addition of KCl (50 mmol/l) to the
culture medium
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lymphocytes of SNS-gp130−/− mice upon antigen-
specific restimulation.
Conclusions
The proinflammatory effect of IL-6 in immune-mediated
arthritis depends in part on the effect of IL-6 on sensory
neurons because the selective deletion of IL-6 signaling
in sensory neurons significantly reduces the inflamma-
tory swelling in the afflicted joint. IL-6 enhances the re-
lease of CGRP evoked by depolarization, a neuropeptide
with strong vasodilator activity, from sensory neurons
thus activating neurogenic mechanisms of inflammation.
In addition, neuronal IL-6 signaling might influence the
systemic cellular inflammatory response because lym-
phocytes from mice without neuronal IL-6 signaling
show enhanced release of IL-17 and IFNγ upon
antigen-specific restimulation. Together the present
data indicate a role of neuronal IL-6 signaling in the
coordination of the whole arthritic process and not
just in the generation of arthritic pain. Rather IL-6
signaling functionally connects the nervous and im-
mune system in a bidirectional way.
Fig. 7 Increase of the CGRP concentration in the knee tissue, the
serum and the spleen during beginning AIA. a. Significant swelling of
the knee joint after induction of AIA. Immunized control mice (IC)
received intraarticular NaCl instead of intraarticular mBSA.
b-d. Enhanced concentration of CGRP in the serum, in the knee
tissue, and in the spleen 6 h after induction of AIA (for knee
joint and spleen CGRP concentration in relation to the total
protein concentration). Values are mean ± SEM, *p < 0.05, **p < 0.01.
AIA antigen-induced arthritis, CGRP calcitonin gene-related peptide,
IC immunized mice which received intraarticular NaCl instead of mBSA,
n.d. not detectable
Fig. 8 Cytokine expression profiles of lymphocytes from naïve SNS-
gp130flox/flox and SNS-gp130−/− mice. Levels of (a) IL-2, (b) IL-17 and
(c) IFNγ in supernatants of unstimulated (w/o) or anti-CD3-stimulated
spleen cells. Additionally, cells were preincubated for 1 h with CGRP
(100 nM or 10 pM) and/or IL-6/sIL-6R (90 ng/ml) before anti-CD3
stimulation. Values (mean ± SEM) are given as absolute concentrations
(pg/ml or ng/ml) or as changes against cytokine concentration of
anti-CD3 stimulation (baseline) in %. *p < 0.05 compared to baseline,
by Wilcoxon’s matched-pairs signed-rank test. n = 6 per group.
CGRP calcitonin gene-related peptide, IFNγ interferon-γ, IL interleukin
sIL-6R soluble IL-6 receptor
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